Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma

Inclusion Criteria

• •Patients who have signed this Written Informed Consent Form after a full explanation about the participation in this study
• •Patients aged 18 years or older Patients diagnosed with a solid malignant tumour or malignant lymphoma that is refractory to standard therapies or for which no standard therapies exist
• •Patients with good physical conditions (you can walk and can look after yourself) within the last 2 weeks.
• •Patients who have at least one lesion that can be accurately assessed